Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Ceftobiprole medocaril

Alternative Names: ceftobiprole medocaril
Latest Update: 2025-04-16
Latest Update Note: News Article

Product Description

a new generation broad-spectrum intravenous cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Ceftobiprole exhibits potent in vitro activity against a number of Gram-positive and Gram-negative pathogens associated with hospital-acquired pneumonia (HAP) and community-acquired pneumonia (CAP). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25117196/)

Mechanisms of Action: PBP Binder

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Colombia | France

Approved Indications: None

Known Adverse Events: None

Company: Basilea Pharmaceutica
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ceftobiprole medocaril

Countries in Clinic: Bulgaria, Estonia, Germany, Latvia, Lithuania, Poland, Slovakia, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Neonatal Sepsis|Sepsis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
BPR-PIP-003

P3

Completed

Neonatal Sepsis

2024-12-18

2022-001837-35

P3

Active, not recruiting

Sepsis

2024-02-19

Recent News Events

Date

Type

Title

04/16/2025

News Article

 Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025

01/28/2025

News Article

 Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea

12/16/2024

News Article

 Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

12/16/2024

News Article

 Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions